Biologics

Tiziana Life Sciences has expanded its pipeline in autoimmune diseases. The company acquired an exclusive world-wide license for Novimmune’s arthritis candidate NI-1201, a human anti-interleukin-6 receptor …

So far only three classes of biosimilar have been approved for use in the EU (somatropins, epoetins and GCSFs), but a second generation of biosimilars is …

After publication of the US-FDA Process Validation Guideline in 2011, the EMA’s Biologics Working Party earlier this year published a draft Guideline on Process Validation for …

Contract Development and Manufacturing Organisations (CDMOs) are playing an increasingly critical role in the large molecule drug market. The biopharmaceutical CDMO market continues to grow in …

Brian Collins brings a wealth of relevant experience to the Company, having spent the last four years as CFO of the Cell and Gene Therapy Catapult …

Prior to joining NorthX, Hoogstraate was CEO of Valneva Sweden. She succeeds Helena Strigård. She will act as an advisor to Janet Hoogstraate in this crucial …

Under the agreement, Schlieren-based LimmaTech Biologics AG receives the exclusive rights from Abbvacc Inc, a recent spin-out from Integrated Biotherapeutics (IBT) LLC, to conduct Phase I …

As part of the US100m acquisition, Ligand Pharmaceuticals Inc  has committed to invest up to US$4m in invIOs Holding AG, Apeiron Biologics AG’s immuno-oncology spin-out. Apeiron shareholders …

With the inauguration of the new production unit P2, which contains fully equipped production lines for 1500 l and 300 l batches with interchangeable product streams …

The Celonic Group is a fast rising, mid-sized biologics CDMO focusing uniquely on mammalian expressed drugs. It provides end to end drug substance development and manufacturing …